BRIEF-Teva CEO says company must regain focus on generics business

Thu May 1, 2014 8:55am EDT

May 1 (Reuters) - Teva Pharmaceutical Industries' new chief executive, Erez Vigodman, says:

* Company must regain focus on generics business

* Will be considering "inorganic opportunities" in biosimilars sector

* Company will start expanding in emerging markets

* Aware of M&A opportunities including potential larger transactions

* Any company launching generic Copaxone "at-risk" faces exposure in the billions of dollars

* FDA should require clinical trials of companies seeking to launch generic Copaxone (Reporting by Tova Cohen and Steven Scheer)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.